8.42
price down icon5.61%   -0.50
after-market Handel nachbörslich: 8.64 0.22 +2.61%
loading
Schlusskurs vom Vortag:
$8.92
Offen:
$9.06
24-Stunden-Volumen:
601.63K
Relative Volume:
0.74
Marktkapitalisierung:
$633.76M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-4.6264
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
-6.76%
1M Leistung:
+35.59%
6M Leistung:
+18.59%
1J Leistung:
+3.19%
1-Tages-Spanne:
Value
$8.37
$9.13
1-Wochen-Bereich:
Value
$8.37
$9.595
52-Wochen-Spanne:
Value
$3.91
$13.98

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name
Firmenname
Eyepoint Pharmaceuticals Inc
Name
Telefon
617-926-5000
Name
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Name
Mitarbeiter
144
Name
Twitter
@eyepointpharma
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
EYPT's Discussions on Twitter

Vergleichen Sie EYPT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
EYPT
Eyepoint Pharmaceuticals Inc
8.42 633.76M 46.02M -70.80M -1.61M -1.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-07 Eingeleitet Citigroup Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-28 Eingeleitet Jefferies Buy
2024-01-22 Eingeleitet JP Morgan Overweight
2023-11-02 Eingeleitet Mizuho Buy
2023-04-21 Eingeleitet Robert W. Baird Outperform
2022-07-07 Eingeleitet Chardan Capital Markets Buy
2021-03-01 Eingeleitet Cowen Outperform
2021-01-28 Eingeleitet Cantor Fitzgerald Overweight
2020-04-06 Herabstufung B. Riley FBR Buy → Neutral
2019-11-04 Fortgesetzt Laidlaw Buy
2019-09-12 Eingeleitet Guggenheim Buy
Alle ansehen

Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten

pulisher
Jun 17, 2025

Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Capital Initiates Coverage on EyePoint Pharmaceuticals (EYPT - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

EyePoint Pharmaceuticals (EYPT) Poised for Success with Positive Outlook | EYPT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar - simplywall.st

Jun 16, 2025
pulisher
Jun 16, 2025

EyePoint (EYPT) Grants Stock Options to New Employees as Inducement | EYPT Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 563 - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals

Jun 16, 2025
pulisher
Jun 16, 2025

EyePoint Awards 12,500 Shares in Stock Options to Three New Hires at $9.03 Per Share - Stock Titan

Jun 16, 2025
pulisher
Jun 14, 2025

(EYPT) Trading Report - news.stocktradersdaily.com

Jun 14, 2025
pulisher
Jun 12, 2025

EyePoint Stock: Retaining My 'Risky Buy' CallPivotal Data Due Early 2026 (NASDAQ:EYPT) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Weighs in on EYPT FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

EyePoint at Goldman Sachs Healthcare Conference: Sustained-Release Vision By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Breakout Momentum Plays You May Not Know About - Investing.com

Jun 09, 2025
pulisher
Jun 07, 2025

Squarepoint Ops LLC Has $302,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Grows Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Raises Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 8,981 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

(EYPT) Investment Report - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $276,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN

May 31, 2025
pulisher
May 31, 2025

Millennium Management LLC Buys New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

May 31, 2025
pulisher
May 30, 2025

EyePoint advances with Duravyu Phase III trial - Yahoo

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com India

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st

May 30, 2025
pulisher
May 30, 2025

EyePoint Pharmaceuticals’ (EYPT) Buy Rating Reaffirmed at HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media

May 29, 2025
pulisher
May 29, 2025

Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus

May 29, 2025
pulisher
May 29, 2025

EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Acquires 145,065 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

May 29, 2025
pulisher
May 28, 2025

EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times

May 28, 2025
pulisher
May 28, 2025

EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan

May 28, 2025
pulisher
May 28, 2025

EYPTEyepoint Pharmac Latest Stock News & Market Updates - Stock Titan

May 28, 2025
pulisher
May 27, 2025

EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com India

May 27, 2025
pulisher
May 27, 2025

JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com UK

May 27, 2025
pulisher
May 27, 2025

Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks

May 27, 2025
pulisher
May 27, 2025

EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq

May 27, 2025
pulisher
May 27, 2025

EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Clinical Trial Milestone: EyePoint's Revolutionary 6-Month Eye Treatment Completes Phase 3 Enrollment - Stock Titan

May 27, 2025
pulisher
May 26, 2025

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail

May 26, 2025
pulisher
May 25, 2025

Deutsche Bank AG Has $1.59 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

May 25, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Purchases New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

May 24, 2025
pulisher
May 22, 2025

(EYPT) Trading Signals - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Northern Trust Corp Has $4.79 Million Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World

May 22, 2025
pulisher
May 19, 2025

Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus

May 19, 2025

Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Eyepoint Pharmaceuticals Inc-Aktie (EYPT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Zaderej Karen L.
Director
May 19 '25
Buy
5.99
5,000
29,950
36,500
Zaderej Karen L.
Director
May 16 '25
Buy
5.81
5,000
29,050
31,500
Zaderej Karen L.
Director
May 15 '25
Buy
5.47
5,000
27,350
26,500
Zaderej Karen L.
Director
May 14 '25
Buy
5.42
5,000
27,100
21,500
Elston George
Chief Financial Officer
Feb 09 '25
Option Exercise
0.00
5,834
0
75,550
Lurker Nancy
Director
Feb 09 '25
Option Exercise
0.00
20,000
0
205,436
Duker Jay S.
President and CEO
Feb 09 '25
Option Exercise
0.00
7,000
0
79,706
Elston George
Chief Financial Officer
Jan 06 '25
Option Exercise
0.00
15,285
0
73,374
Elston George
Chief Financial Officer
Jan 05 '25
Option Exercise
0.00
15,000
0
63,356
Lurker Nancy
Director
Jan 06 '25
Option Exercise
0.00
75,134
0
185,436
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Kapitalisierung:     |  Volumen (24h):